Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis
- Deneau, Mark R
- Mack, Cara
- Abdou, Reham
- Amin, Mansi
- Amir, Achiya
- Auth, Marcus
- Bazerbachi, Fateh
- Marie Broderick, Anne
- Chan, Albert
- DiGuglielmo, Matthew
- El-Matary, Wael
- El-Youssef, Mounif
- Ferrari, Federica
- Furuya, Katryn N
- Gottrand, Frederic
- Gupta, Nitika
- Homan, Matjaž
- Jensen, M K
- Kamath, Binita M
- Mo Kim, Kyung
- Kolho, Kaija-Leena
- Konidari, Anastasia
- Koot, Bart
- Iorio, Raffaele
- Martinez, Mercedes
- Mohan, Parvathi
- Palle, Sirish
- Papadopoulou, Alexandra
- Ricciuto, Amanda
- Saubermann, Lawrence
- Sathya, Pushpa
- Shteyer, Eyal
- Smolka, Vratislav
- Tanaka, Atsushi
- Valentino, Pamela L
- Varier, Raghu
- Venkat, Veena
- Vitola, Bernadette
- Vos, Miriam B
- Woynarowski, Marek
- Yap, Jason
- Miloh, Tamir
DOIAbstract
Adverse clinical events in primary sclerosing cholangitis (PSC) happen too slowly to capture during clinical trials. Surrogate endpoints are needed, but no such validated endpoints exist for children with PSC. We evaluated the association between gamma glutamyltransferase (GGT) reduction and long-term outcomes in pediatric PSC patients. We evaluated GGT normalization ( 75% versus 75% by 1 year after PSC diagnosis predicts favorable 5-year outcomes in children. GGT has promise as a potential surrogate endpoint in future clinical trials for pediatric PSC